Pemetrexed/Cisplatin

DRUG8 trials

Sponsors

Spanish Lung Cancer Group, Chang Gung Memorial Hospital, Pfizer, European Organisation for Research and Treatment of Cancer - EORTC, Memorial Sloan Kettering Cancer Center

Conditions

Advanced Non-Squamous Non-Small Cell Lung CancerCarcinoma, Non Small Cell LungMalignant Pleural MesotheliomaNSCLC (Non-small Cell Lung Cancer)Non Small Cell Lung CancerNon-Small Cell Lung CancerNon-small Cell Lung Cancer

Phase 1

Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma

WithdrawnNCT02639767

Memorial Sloan Kettering Cancer CenterMalignant Pleural Mesothelioma

Start: 2015-12-31Updated: 2016-12-07

Phase 2

Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC

TerminatedNCT01088906

Spanish Lung Cancer GroupCarcinoma, Non Small Cell Lung

Start: 2010-01-31End: 2014-04-30Updated: 2024-10-15

Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation

CompletedNCT01204307

Chang Gung Memorial HospitalAdvanced Non-Squamous Non-Small Cell Lung Cancer

Start: 2010-01-31End: 2015-06-30Updated: 2015-07-28

Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM

European Organisation for Research and Treatment of Cancer - EORTCMalignant Pleural Mesothelioma

Start: 2016-09-20End: 2023-09-30Target: 64Updated: 2022-11-07

Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC

Guangzhou Medical UniversityNon Small Cell Lung Cancer

Start: 2016-12-01End: 2021-12-30Target: 178Updated: 2019-03-28

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

RecruitingNCT05061550

AstraZenecaNon-small Cell Lung Cancer

Start: 2022-04-14End: 2030-05-28Target: 630Updated: 2026-03-11

Phase 3

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

CompletedNCT01639001

PfizerNSCLC (Non-small Cell Lung Cancer)

Start: 2012-09-29End: 2020-01-08Updated: 2020-12-08

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

Active, not recruitingNCT04035486

AstraZenecaNon-Small Cell Lung Cancer

Start: 2019-07-02End: 2026-12-22Updated: 2025-10-10

Related Papers

Survival with Osimertinib plus Chemotherapy in <i>EGFR</i>-Mutated Advanced NSCLC.

2025-10-171 citations

Population Pharmacokinetics and Exposure‐Response Analysis of First‐Line Osimertinib Plus Chemotherapy in Patients with <scp>EGFR</scp> ‐Mutated Advanced <scp>NSCLC</scp>

Clinical Pharmacology & Therapeutics2025-07-104 citations

Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.

2025-05-316 citations

Ethnic disparities in clinical trials for FDA-approved drugs in lung cancer: A post-COVID era analysis (2020-2024).

Journal of Clinical Oncology2025-05-28

Neoadjuvant durvalumab (D) + chemotherapy (CT) + novel anticancer agents and adjuvant D ± novel agents in resectable non-small-cell lung cancer (NSCLC): Updated outcomes from NeoCOAST-2.

Journal of Clinical Oncology2025-05-28

EGFR mutation testing across the osimertinib clinical program.

2025-04-182 citations

BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer.

2024-10-219 citations

PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer

Future Oncology2024-07-1830 citations

A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice

Cancers2024-03-0716 citations

4O First-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: FLAURA2 post-progression outcomes

ESMO Open2024-03-0122 citations

10P Safety and tolerability of first-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFRm advanced NSCLC: Data from FLAURA2

ESMO Open2024-03-014 citations

9P First-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFRm advanced NSCLC: FLAURA2 patient-reported outcomes (PROs)

ESMO Open2024-03-012 citations

Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.

2023-12-1929 citations

Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC

New England Journal of Medicine2023-11-08530 citations

NeoCOAST-2: A phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant durvalumab plus novel IO or volrustomig alone in patients with resectable non-small-cell lung cancer (NSCLC).

Journal of Clinical Oncology2023-06-0110 citations

First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors

Cancer Immunology Immunotherapy2023-04-0589 citations

Abstract CT124: NeoCOAST-2: a randomized, open-label, phase 2 study of neoadjuvant durvalumab plus novel immunotherapies and chemotherapy (CT) followed by adjuvant durvalumab plus novel agents, in patients with resectable non-small-cell lung cancer (NSCLC)

Cancer Research2022-06-153 citations

Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study.

2021-09-1754 citations

Neoadjuvant Osimertinib With/Without Chemotherapy Versus Chemotherapy Alone for <i>EGFR</i> -Mutated Resectable Non-Small-Cell Lung Cancer: NeoADAURA

Future Oncology2021-07-19180 citations

Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC.

2020-12-15137 citations

3 more papers not shown